Selectivity and Long Action of <i>In Vivo</i> Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Compared to FDA-Approved Prostacyclin Agonists Iloprost and Selexipag in the Prevention of Thrombosis
Livia Stanger(University of Michigan), Michael Holinstat(Thomas Jefferson University), Björn Dahlöf, Krista Goerger(University of Michigan), Mariane Flores(University of Michigan)
Cited by 0
Related Papers
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
|The Lancet|2019|785
An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis
|Cell|2024|102
Protein Kinase C Regulation of 12-Lipoxygenase-Mediated Human Platelet Activation
|Molecular Pharmacology|2011|44
Antiplatelet strategies: past, present, and future
|Journal of Thrombosis and Haemostasis|2023|39